5
Oct
2018
Nobel Highlights and Lowlights, MSK Fallout Continues, Pfizer CEO Stepping Down
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account. 
Share:
3
Oct
2018
Overcoming a Bad Job Market, Finding a Path in Biotech: Sabah Oney on The Long Run
Today’s guest on The Long Run is Sabah Oney. He’s the chief business officer of South San Francisco-based Alector. You could be excused if you’ve never heard of Alector or Sabah Oney. Neither makes a lot of noise. But Oney is an up-and-comer, and the company has been on my radar for some time. Alector is a serious drug discovery...Read More
Share:
28
Sep
2018
Roche’s PD-L1 ‘Practice-Changer,’ J&J Dumps Geron, and Amarin’s Fish-Oil Surprise
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
21
Sep
2018
WuXi Eyes A Fresh $1B, California Aims at AbbVie, and MSK’s Industry Ties in the Spotlight
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
19
Sep
2018
Health Data That Can Meet Pharma Standards: Amy Abernethy on The Long Run
Amy Abernethy is the latest guest on The Long Run podcast. Amy is the chief medical and chief scientific officer of Flatiron Health in New York City. She’s an MD/PhD, and previously was a tenured professor at Duke University. She made a name for herself there with more than 400 peer-reviewed publications. She honed her ideas there around using technology...Read More
Share:
14
Sep
2018
Baselga Brouhaha, a Shkreli Imitator, and Autoimmunity Strides from BMS and Gilead
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
5
Sep
2018
Telling Biotech Stories on TV: Listen to Meg Tirrell on The Long Run Podcast
Today’s guest on The Long Run is Meg Tirrell. Meg is the biotech and pharmaceuticals reporter at CNBC. This is a big job. People that control billions in investment dollars regularly keep an eye on the cable TV investment channel for breaking news and analysis on interest rates, the stock market, currencies and more. Meg makes sure they get timely,...Read More
Share:
5
Sep
2018
Fulcrum Gets $80M to Test Small Molecules Against Rare Disorders of Gene Expression
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
28
Aug
2018
Time and Money: What Are They Worth to a Young Scientist?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
24
Aug
2018
Exact Goes from Madison Wis. to Madison Ave. & IPO Candidates Get in Line
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
22
Aug
2018
Building Startups With Pharma Needs in Mind: Thong Le on The Long Run Podcast
Today’s guest on The Long Run podcast is Thong Le. Le is the CEO of Accelerator Life Science Partners. It’s a venture capital backed operation that starts and nurtures biotech startups in Seattle, New York, San Diego and other places outside the main industry clusters of Boston and San Francisco. Accelerator, founded in 2003, currently invests out of a $63...Read More
Share:
17
Aug
2018
Alnylam Crosses the Threshold, Gilead’s Changing of the Guard & Gene Therapy Financings Galore
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
8
Aug
2018
The Antibiotic Opportunity? Spero’s Ankit Mahadevia on The Long Run Podcast
Today’s guest on The Long Run podcast is Ankit Mahadevia. Mahadevia is the CEO of Cambridge, Mass.-based Spero Therapeutics. It’s an antibiotic developer. Specifically, it’s focused on new strategies for fighting gram-negative bacterial infections that are increasingly resistant to our existing set of antibiotics. Despite persistent warnings from global health authorities about the rise of multi-drug resistant bugs, and the...Read More
Share:
7
Aug
2018
5AM, NEA Lead $50M Bet on Akouos, Crafting Gene Therapy for the Ear
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
3
Aug
2018
BeiGene’s Cash Haul, Illumina’s Big Q2, & Startups Keep Hiring Pharma Vets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
31
Jul
2018
Verana, Backed by GV & Brook Byers, Grabs $30M to Squeeze Meaning Out of EMRs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
27
Jul
2018
An Alzheimer’s Hope-Fest, GSK Cozies Up to 23andMe, & A Gilead Legend Steps Aside
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
26
Jul
2018
Betting on Biotech IPOs? What If You Buy the Third Rock and ARCH Portfolios?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
25
Jul
2018
Alector, Staying Private for Now, Pulls in $133M for Alzheimer’s R&D
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
25
Jul
2018
Finding the ‘Middle Market’ of Biotech VC: Chris Garabedian on The Long Run Podcast
Today’s guest on The Long Run podcast is Chris Garabedian. Garabedian is best known for his controversial stint as CEO of Cambridge, Mass.-based Sarepta Therapeutics, the developer of treatments for Duchenne Muscular Dystrophy. Whatever you may think of his tenure there — and the FDA’s decision to approve eteplirsen on a slim reed of clinical trial evidence – there is...Read More
Share: